Biltmore Capital Advisors LLC trimmed its holdings in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 18.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,380 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Biltmore Capital Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $71,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Creative Planning acquired a new position in Catalyst Pharmaceuticals during the 3rd quarter worth $84,000. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at $5,752,000. Emerald Advisers LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at $6,244,000. California Public Employees Retirement System lifted its holdings in shares of Catalyst Pharmaceuticals by 106.8% in the third quarter. California Public Employees Retirement System now owns 136,253 shares of the biopharmaceutical company’s stock valued at $724,000 after buying an additional 70,358 shares during the period. Finally, Gables Capital Management Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 0.9% in the third quarter. Gables Capital Management Inc. now owns 490,564 shares of the biopharmaceutical company’s stock valued at $2,606,000 after buying an additional 4,500 shares during the period. 60.21% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently weighed in on CPRX shares. Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 9th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, October 31st. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Wednesday, July 31st. SunTrust Banks restated a “buy” rating and issued a $11.00 price objective (up previously from $9.00) on shares of Catalyst Pharmaceuticals in a report on Thursday, August 8th. Finally, ValuEngine lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $8.63.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The firm had revenue of $28.84 million during the quarter, compared to analyst estimates of $17.99 million. The company’s quarterly revenue was up 2883900.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.06) EPS. As a group, research analysts forecast that Catalyst Pharmaceuticals Inc will post 0.34 earnings per share for the current year.
In other news, Director Charles B. O’keeffe acquired 10,000 shares of the business’s stock in a transaction dated Friday, October 11th. The stock was acquired at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the acquisition, the director now directly owns 553,376 shares in the company, valued at approximately $2,600,867.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.70% of the company’s stock.
Catalyst Pharmaceuticals Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Further Reading: What is a stock buyback?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.